Can technological solutions for diabetes replace islet cell function?

Organogenesis

Volumn 7, Issue 1, 2011, Pages 32-41

  Gregory, Justin M ^a   Moore, Daniel J ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Artificial pancreas; Closed loop control; Continuous glucose monitor; Diabetes; Hyperglycemia

Indexed keywords

GLUCOSE; INSULIN;

ALGORITHM; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN PUMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; ISLETS OF LANGERHANS;

EID: 79952436028     PISSN: 15476278     EISSN: 15558592     Source Type: Journal    
DOI: 10.4161/org.7.1.14028     Document Type: Review

References (99)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-86.
3. Dall TM, et al. The Economic Burden Of Diabetes. Health Aff (Millwood) 2010.
4. National Diabetes Fact Sheet 2007.
5. Fong DS, et al. Retinopathy in diabetes. Diabetes Care 2004; 27:84-7.
6. Donnelly R, et al. ABC of arterial and venous disease: vascular complications of diabetes. BMJ 2000; 320:1062-6. (Pubitemid 30198980)
7. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328:1676-85. (Pubitemid 23157351)
8. Onkamo P, et al. Worldwide increase in incidence of Type I diabetes - the analysis of the data on published incidence trends. Diabetologia 1999; 42:1395-403. (Pubitemid 30012309)
9. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 2006; 23:857-66.
10. Vehik K, et al. Increasing incidence of type 1 diabetes in 0 to 17 year-old Colorado youth. Diabetes Care 2007; 30:503-9. (Pubitemid 46354325)
11. Bryden KS, et al. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care 2003; 26:1052-7. (Pubitemid 36929247)
12. Ben-Ami H, et al. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999; 159:281-4. (Pubitemid 29075648)
13. Laing SP, et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16:466-71.
14. Banting F. In Nobel Lecture, Nobel Foundation.
15. Gabbay KH, Korff J, Schneeberger EE. Vesicular binesis: glucose effect on insulin secretory vesicles. Science 1975; 187:177-9.
16. Porte D Jr, Pupo AA. Insulin responses to glucose: evidence for a two pool system in man. J Clin Invest 1969; 48:2309-19.
17. Chen M, Porte D Jr. The effect of rate and dose of glucose infusion on the acute insulin response in man. J Clin Endocrinol Metab 1976; 42:1168-75.
18. Fukumoto H, et al. Sequence, tissue distribution and chromosomal localization of mRNA encoding a human glucose transporter-like protein. Proc Natl Acad Sci USA 1988; 85:5434-8.
19. Permutt MA, et al. Cloning and functional expression of a human pancreatic islet glucose-transporter cDNA. Proc Natl Acad Sci USA 1989; 86:8688-92. (Pubitemid 20010289)
20. Unger RH. Diabetic hyperglycemia: link to impaired glucose transport in pancreatic beta cells. Science 1991; 251:1200-5. (Pubitemid 21926211)
21. Rajan AS, et al. Ion channels and insulin secretion. Diabetes Care 1990; 13:340-63. (Pubitemid 20092118)
22. Bogardus C, Tataranni PA. Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. Diabetes 2002; 51:262-4.
23. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:214-23.
24. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996; 19:278-86.
25. Fransson U, et al. Anaplerosis via pyruvate carboxylase is required for the fuel-induced rise in the ATP:ADP ratio in rat pancreatic islets. Diabetologia 2006; 49:1578-86. (Pubitemid 43848094)
26. Crespin SR, Greenough WB, 3rd, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest 1969; 48:1934-43.
27. Levin SR, et al. Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes 1971; 20:171-6.
28. Kreymann B, et al. Glucagon-like peptide-1-7-36: a physiological incretin in man. Lancet 1987; 2:1300-4. (Pubitemid 17156636)
29. Dupre J, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37:826-8.
30. Miller RE. Pancreatic neuroendocrinology: peripheral neural mechanisms in the regulation of the Islets of Langerhans. Endocr Rev 1981; 2:471-94.
31. Frohman LA, Ezdinli EZ, Javid R. Effect of vagotomy and vagal stimulation on insulin secretion. Diabetes 1967; 16:443-8.
32. Louis-Sylvestre J. Preabsorptive insulin release and hypoglycemia in rats. Am J Physiol 1976; 230:56-60.
33. Benthem L, Mundinger TO, Taborsky GJ Jr. Meal-induced insulin secretion in dogs is mediated by both branches of the autonomic nervous system. Am J Physiol Endocrinol Metab 2000; 278:603-10.
34. Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001; 50:1030-8. (Pubitemid 32374533)
35. Hansen BC, et al. Rapid oscillations in plasma insulin, glucagon and glucose in obese and normal weight humans. J Clin Endocrinol Metab 1982; 54:785-92. (Pubitemid 13240840)
36. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81:442-8. (Pubitemid 18075238)
37. Meda P, et al. Direct communication of homologous and heterologous endocrine islet cells in culture. J Cell Biol 1982; 92:221-6. (Pubitemid 12138129)
38. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57:3169-76.
39. Grodsky GM, et al. Effect of pulse administration of glucose or glucagon on insulin secretion in vitro. Metabolism 1967; 16:222-33.
40. Curry DL, Bennett LL, Li CH. Direct inhibition of insulin secretion by synthetic somatostatin. Biochem Biophys Res Commun 1974; 58:885-9.
41. Koerker DJ, et al. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 1974; 184:482-4.
42. Ferrannini E, et al. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 1983; 244:517-27.
43. Argaud D, et al. Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5'-flanking sequence. Diabetes 1996; 45:1563-71. (Pubitemid 26357550)
44. O'Brien RM, Granner DK. PEPCK gene as model of inhibitory effects of insulin on gene transcription. Diabetes Care 1990; 13:327-39. (Pubitemid 20092117)
45. Kadish AH. Automation control of blood sugar. I. A servomechanism for glucose monitoring and control. Am J Med Electron 1964; 3:82-6.
46. Pfeiffer EF, Thum C, Clemens AH. The artificial beta cell - a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). Horm Metab Res 1974; 6:339-42.
47. Albisser AM, et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974; 23:397-404.
48. Albisser AM, et al. An artificial endocrine pancreas. Diabetes 1974; 23:389-96.
49. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm Metab Res 1977; 7:23-33.
50. Fogt EJ, et al. Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system (Biostator). Clin Chem 1978; 24:1366-72. (Pubitemid 8392017)
51. Clemens AH, Hough DL, D'Orazio PA. Development of the Biostator Glucose clamping algorithm. Clin Chem 1982; 28:1899-904. (Pubitemid 12032833)
52. Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005; 7:28-47. (Pubitemid 40354574)
53. Heinemann L, Ampudia-Blasco FJ. Glucose clamps with the Biostator: a critical reappraisal. Horm Metab Res,1994; 26:579-83. (Pubitemid 24381116)
54. Brennan JR, Gebhart SS, Blackard WG. Pump-induced insulin aggregation. A problem with the Biostator. Diabetes 1985; 34:353-9.
55. Hovorka R. The future of continuous glucose monitoring: closed loop. Curr Diabetes Rev 2008; 4:269-79.
56. Skyler JS. Continuous glucose monitoring: an overview of its development. Diabetes Technol Ther 2009; 11:5-10.
57. Kovatchev BP, et al. In silico preclinical trials: A proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009; 3:44-55.
58. Kovatchev B, et al. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care 2008; 31:1160-4.
59. Weinzimer SA, Tamborlane WV. Sensor-augmented pump therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008; 15:118-22. (Pubitemid 351651723)
60. Garg S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006; 29:44-50. (Pubitemid 44033429)
61. Deiss D, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29:2730-2. (Pubitemid 44912209)
62. The accuracy of the Guardian RT continuous glucose monitor in children with type 1 diabetes. Diabetes Technol Ther 2008; 10:266-72.
63. Connor H, Atkin G, Attwood E. Short-term control of brittle diabetes using a Biostator. Br Med J (Clin Res Ed) 1982; 285:1316-7. (Pubitemid 12036884)
64. Verdonk CA, et al. Glucose clamping using the Biostator GCIIS. Horm Metab Res 1980; 12:133-5. (Pubitemid 10096945)
65. Hipszer B, Joseph J, Kam M. Pharmacokinetics of intravenous insulin delivery in humans with type 1 diabetes. Diabetes Technol Ther 2005; 7:83-93. (Pubitemid 40354578)
66. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2006; 23:1-12.
67. Ferrannini E, Linde B, Faber O. Effect of bicycle exercise on insulin absorption and subcutaneous blood flow in the normal subject. Clin Physiol 1982; 2:59-70. (Pubitemid 12146279)
68. Koivisto VA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. N Engl J Med 1978; 298:79-83. (Pubitemid 8260215)
69. Marliss EB, Vranic M. Intense exercise has unique effects on both insulin release and its roles in glucoregulation: implications for diabetes. Diabetes 2002; 51:271-83.
70. Ertl AC, Davis SN. Evidence for a vicious cycle of exercise and hypoglycemia in type 1 diabetes mellitus. Diabetes Metab Res Rev 2004; 20:124-30. (Pubitemid 38489661)
71. 125I-insulin absorption and blood glucose concentration. Diabetologia 1979; 17:291-5.
72. 125I-NPH insulin in diabetic patients. Horm Metab Res 1983; 15:274-8.
73. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4:673-82.
74. Heinemann L, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21:1910-4.
75. Renard E, et al. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 2006; 32:497-502. (Pubitemid 44836980)
76. Schaepelynck Belicar P, Vague P, Lassmann-Vague V. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. Diabetes Metab 2003; 29:344-8. (Pubitemid 37187102)
77. Broussolle C, Jeandidier N, Hanaire-Broutin H. French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. Lancet 1994; 343:514-5.
78. Gin H, et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab 2003; 29:602-7. (Pubitemid 38082162)
79. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004; 56:125-44. (Pubitemid 38114927)
80. Kuzuya T, et al. Comparison of the early time courses of the release of insulin that follow injections of tetragastrin, tolbutamide, xylitol and glucose into the pancreatic artery of dogs. Diabetes 1978; 27:1189-95. (Pubitemid 9095998)
81. Steil GM, et al. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006; 55:3344-50. (Pubitemid 44923591)
82. Rawlings JB. Tutorial overview of model predictive control. IEEE Control Systems Magazine 2000; 20:38-52.
83. Mayne DQ, et al. Constrained model predictive control: stability and optimality. Automatica 2000; 36:789-814. (Pubitemid 30587683)
84. Magni L, et al. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007; 1:804-12.
85. Weinzimer SA, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type1 diabetes using an artificial pancreas. Diabetes Care 2008; 31:934-9.
86. Hovorka R, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375:743-51.
87. Renard E, et al. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010; 33:121-7.
88. King DS, et al. Effects of lack of exercise on insulin secretion and action in trained subjects. Am J Physiol 1988; 254:537-42.
89. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab 1987; 65:30-6.
90. Palmer JP, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop 21-22 October 2001. Diabetes 2004; 53:250-64.
91. Cernea S, et al. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009; 25:694-704.
92. Ryan EA, et al. Assessment of the severity of hypoglycemia and glycemic lability in type1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53:955-62. (Pubitemid 38436607)
93. Rickels MR, et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes 2005; 54:3205-11. (Pubitemid 43334376)
94. Alejandro R, et al. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation 2008; 86:1783-8.
95. Davalli AM, et al. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995; 59:817-20.
96. Bierhaus A, et al. Diabetes-associated sustained activation of the transcription factor nuclear factorkappaB. Diabetes 2001; 50:2792-808. (Pubitemid 33733131)
97. Maedler K, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-60.
98. Aljada A, et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism 2006; 55:1177-85. (Pubitemid 44215936)
99. Montolio M, et al. Role of blood glucose in cytokine gene expression in early syngeneic islet transplantation. Cell Transplant 2007; 16:517-25. (Pubitemid 351448287)